TNF and Opportunistic infection: Among the first drugs of this group to be incorporated into clinical practice are the tumor necrosis factor-alpha inhibitors (TNF-ɑ inhibitors, also called Anti-TNF-ɑ), approved by the Food and Drug Administration (FDA) in the 1990s.[7–11] However, even though they are considered fundamental in rescue therapy for refractory diseases, they have great potential to block the immune response necessary against infections.[12–15] Thus, patients using these drugs are at an increased risk of opportunistic infections, notably tuberculosis.[16]